Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Biomarker Profiles in Asia Pacific erbB2+/HER2 Breast Cancer Patients Treated With Lapatinib and Other Anti-erbB2/HER2 Therapy

NCT01248897 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01248897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01248897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Biomarker Profiles in Asia Pacific erbB2+/HER2 Breast Cancer Patients Treated With Lapatinib and Other Anti-erbB2/HER2 Therapy
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
August 17, 2010
Completion date
September 5, 2014
Enrollment
158 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, metastasis